Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced the appointment of Anna Novoseletsky as Executive Vice President, General Counsel and Secretary. In this role, Novoseletsky will lead Conduent's global legal, compliance, risk and HR functions and serve as a member of the company's executive leadership team. “Anna is an accomplished legal executive with deep expertise in public company go...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

NEW YORK--(BUSINESS WIRE)--Saba Capital Income & Opportunities Fund II (NYSE: SABA) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, declared a monthly dividend of $0.058 per share on July 31, 2026, payable on August 31, 2026 to shareholders of record as of August 11, 2026. Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby t...

NEW YORK--(BUSINESS WIRE)--Saba Capital Income & Opportunities Fund (NYSE: BRW) (the “Fund”), a registered closed-end management investment company listed on the New York Stock Exchange, declared a monthly dividend of $0.085 per share on July 31, 2026, payable on August 31, 2026 to shareholders of record as of August 11, 2026. Managed Distribution Plan. The above distribution was declared in accordance with the Fund’s currently effective managed distribution plan (the “Plan”), whereby the F...

IRVINE, Calif.--(BUSINESS WIRE)--Phoenix Energy One, LLC ("Phoenix Energy") has begun the finalist selection process for the 2026 Phoenix Energy Scholarship, a $15,000 award established by Phoenix Energy CEO Adam Ferrari to support the next generation of leaders in the American oil and gas industry. With the application period now closed, the Scholarship Committee is reviewing submissions and will select three finalists before announcing this year's recipient on September 1. Now in its fourth y...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Balyasny Asset Management L.P. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be...

PORTLAND, Ore.--(BUSINESS WIRE)--Payfinia, an independent payment services firm providing an open payments framework, today announced a strategic partnership with Dublin, Calif.-based Patelco Credit Union (‘Patelco’ – $9.5 billion in assets and more than 550,000 members), marked by the credit union’s investment* in the Payfinia Credit Union Service Organization (CUSO). As part of the partnership, Patelco’s Chief Technology Officer, Kal Majmundar, has joined the Payfinia CUSO Board of Directors,...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...